Cardiol Therapeutics Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
157.5M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Healthcare
Drug Manufacturers - Specialty & Generic
TSX
Key Financial Metrics
-
Revenue
-36.7M
Net Income
C$-0.51
EPS (Diluted)
-25.1M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-39.9M
Returns & Efficiency
Return on Assets (ROA)
-115.1%
Return on Equity (ROE)
-148.3%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
31.9M
Total Debt
158,532
Debt to Equity
0.01x
Current Ratio
4.52
Company Info
| Industry | Drug Manufacturers - Specialty & Generic |
| HQ | Oakville, Canada |
| Employees | 18 |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.cardiolrx.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
400,002
Shares Sold
0
Total Transactions
8
SEDAR+ Filings
View All Filings15
Quarterly Reports
15
MD&A
73
News Releases
12
Material Changes
16
Prospectuses
6
Governance
32
Certifications
86
Other
Interactive Charts
Company Profile
General Information
| Company Name | Cardiol Therapeutics Inc. |
| Ticker | CRDL.TO |
| Exchange | TSX |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Headquarters | Oakville, Canada |
| Employees | 18 |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.cardiolrx.com |
Financial Summary
| Market Cap | 157.5M |
| Revenue | N/A |
| Net Income | -36.7M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.51 |
| Net Margin | N/A |
| ROE | -148.3% |
| Dividend Yield | N/A |
Business Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.